EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease
BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization…
Find all the latest worldwide news and in-depth articles related to Alzheimer. This section includes the latest research, collaboration deals, and technology advancements of alzheimer’s biotech companies.
BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization…
The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for…
Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma…
A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm…
Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special…
Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective…
A huge step forward in dementia research has been hailed a truly historic moment by…
Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT…
2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO…
In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a…
Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application…
Positive phase 2a clinical data from an Alzheimer's disease (AD) biomarker study, has been announced…